Novanta (NOVT) Q3 2026 earnings review
Novanta's orders and sales accelerate, but deal costs trim profit
Novanta, a supplier of precision parts for medical and factory equipment, grew underlying sales faster while deal financing costs began to bite. Sales from businesses owned a year ago rose 10%, and chief executive Matthijs Glastra reported a 29% jump in customer orders after leaving order numbers out last quarter. Third-quarter profit per share excluding one-offs beat the plan at $1.05, but the company trimmed its full-year profit per share forecast and set the fourth-quarter range below what its prior outlook implied by our math.
| Sales from businesses owned a year ago | +9.9% +9.3% last quarter |
|---|---|
| Reported revenue | $305.0M +23% from a year ago |
| Profit per share, excluding one-offs | $1.05 +21% from a year ago |
| Full-year profit per share outlook | Cut $0.025 middle of the range: $3.66–3.71 |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because stronger orders and a rebound in medical gross margins were offset by the financing drag of the $1.2 billion Riverpoint Medical purchase. Bringing back the order disclosure eased a transparency concern, and overhead costs shrank as a share of sales. The bad news: new debt interest and an 18% larger share count absorb almost all of the fourth quarter's operating profit growth, leaving per-share profit up only 0% to 5%.
The question now is whether Riverpoint brings fast-growing surgical consumables that lift per-share profit or just adds debt and shares that mask slower growth in the older medical products. If the deal adds to the bottom line, profit per share will grow closer to EBITDA once the initial financing step-up passes; if debt and dilution dominate, per-share growth stays muted. The standalone Riverpoint numbers in the third-quarter filing and fourth-quarter profit margins will tell.
🐂 Bull Case
Orders Returned and Underlying Sales Accelerated
Novanta's customer orders and sales from businesses it owned a year ago both grew faster this quarter. After leaving order numbers out of last quarter's update, chief executive Matthijs Glastra reported that "Customer bookings increased 29%, reflecting strong commercial momentum and providing a solid foundation for future growth, expanding our backlog to $543 million". Because orders typically turn into sales over two to three quarters, that order book supports demand into next year.
- Underlying sales growth: 9.9% from a year ago, up from 9.3% in the second quarter
- Total revenue: $305.0 million, up 23.1% from a year ago and $1.0 million above the top of the plan
- Full-year underlying growth outlook: held at about 7%, which by our math leaves 5.6% for the fourth quarter
Novanta has now beaten the top end of its quarterly revenue plan for six straight quarters. By our math, the full-year outlook points to slower underlying growth in the fourth quarter, even though last year's comparison is still easy.
What to watch: fourth-quarter underlying sales growth against the 5.6% rate implied by the full-year plan. Another result near 9% would show that management's fourth-quarter forecast was cautious rather than a sign of cooling demand.
Medical Margins Rebounded and Overhead Costs Shrank
Profit margins in Medical Solutions, the division that sells components and consumables to medical-device makers, bounced back from last quarter's low. Gross margin excluding one-offs in the medical unit rose to 43.9% from 41.1% in the second quarter as the Riverpoint Medical acquisition joined the business. Across the whole company, selling and administrative overhead fell by 1.8 percentage points of revenue to 18.9%, while research and development fell by 1.1 points to 8.6%.
That cost discipline lifted the company's EBITDA margin excluding one-offs by 2.9 percentage points from a year ago to 26.3%, beating the outlook. Still, the medical unit's gross margin excluding one-offs remains 1.4 percentage points below the 45.3% it earned a year ago, and unallocated factory costs stayed near $0.9 million.
What to watch: Medical Solutions gross margin excluding one-offs in the fourth quarter, the first full quarter of Riverpoint ownership. A reading above 45.3% would show that higher-margin surgical consumables and factory closures have overcome the unit's earlier cost drag.
🐻 Bear Case
Debt Costs and New Shares Hold Back Fourth-Quarter Profit
Glastra said that "The third quarter marked a significant milestone for Novanta as we closed the largest acquisition in our history and delivered strong financial results that exceeded our expectations". Novanta paid $1.20 billion in cash for Riverpoint Medical and borrowed $626 million under its credit facilities. Even though third-quarter profit per share excluding one-offs beat the plan by 7.5 cents at the middle of the range, the company trimmed its full-year profit per share outlook by 2.5 cents.
- Fourth-quarter profit per share plan, excluding one-offs: $0.91 to $0.96, down from $0.98 to $1.09 implied three months ago by our math
- Fourth-quarter profit per share growth vs EBITDA growth: 2.7% vs 27.7% at the middle of the ranges by our math
- Diluted share count: 42.7 million, up 18.5% from 36.0 million a year ago
- Net interest expense: $8.3 million in the third quarter, up from $1.1 million in the second quarter
This matters because the financing costs of the deal absorb almost all of the operating profit it adds in the fourth quarter. A larger share count from recent equity raises and higher interest bills leave shareholders with little per-share gain this quarter.
What to watch: net interest expense and the diluted share count in the fourth quarter and after the January 2027 milestone payment. If interest and share dilution keep absorbing more than 20 percentage points of EBITDA growth, per-share profit will lag revenue into 2027.
Acquired Sales Carried Medical While Charges Erased Net Income
Glastra said that "Riverpoint Medical is performing in line with expectations as we continue to make meaningful progress on our operational synergies, while driving an exciting new product pipeline". Across Novanta, acquisitions added $32.9 million to third-quarter revenue. Because Riverpoint sits inside Medical Solutions and that division grew by $37.1 million in total, by our math the older medical products grew only about 3.4% from a year ago, while Automation Enabling Technologies grew 16.0%.
At the same time, deal and restructuring charges wiped out almost all reported profit. Novanta booked $51.2 million of pre-tax adjustments—including $21.4 million of intangible amortization, $19.2 million of acquisition costs and $3.9 million of restructuring—leaving $2.0 million of reported net income against $45.0 million excluding one-offs.
What to watch: the standalone revenue and profit table for Riverpoint Medical in the third-quarter 10-Q filing. That disclosure will show the exact price multiple Novanta paid and how fast the existing medical business grew on its own.
Automation Gross Margin Stepped Down From Last Quarter's Peak
Automation Enabling Technologies, which makes precision motors, lasers and sensors for factory and warehouse equipment, saw its gross margin pull back from last quarter's high. Reported gross margin in the division fell by 2.4 percentage points from 52.6% in the second quarter to 50.2% in the third quarter, while the measure excluding one-offs dropped from 53.4% to 50.9%.
Last quarter's margin benefitted from tariff duty refunds that do not repeat every period. Even after the step-down, the division's reported gross margin stood 2.9 percentage points higher than the 47.3% it recorded a year ago on 16.0% higher sales.
What to watch: Automation Enabling Technologies gross margin in the fourth quarter. A further drop toward 48% would show that the second-quarter jump came mostly from temporary duty refunds rather than permanent factory savings.
Risks this quarter didn't answer
Three standing concerns from last quarter cannot be checked from the earnings release alone and depend on the quarterly filing or conference call.
- Riverpoint standalone financials: the release gives $32.9 million of combined acquisition revenue, leaving Riverpoint's exact run-rate and purchase multiple for the 10-Q business combinations note.
- Factory closures under the 2025 restructuring plan: Novanta booked $3.9 million of restructuring costs, but the 10-Q restructuring note will show whether the delayed site closures finished.
- Tariff and shipping cost exposure: the release does not quantify duty drawbacks or freight costs, which management typically addresses in the filing's margin discussion.
💲 Other KPIs
Swung from $479.9 million of net cash at the end of the second quarter to $689.4 million of net debt after Novanta paid $1.20 billion for Riverpoint Medical. Gross debt rose from $238.8 million to $838.6 million as the equipment maker drew $626.0 million on its credit facilities, while cash fell to $149.2 million.
Rose more than fourfold from $8.5 million a year ago, though down from $64.9 million in the second quarter. Nine-month operating cash flow reached $155.9 million against $55.3 million last year as inventory spending slowed to $2.0 million. Free cash flow—operating cash flow less net factory equipment spending—was $31.5 million.
🔮 Guidance
Unchanged at the middle of the range. The plan calls for 19.6% reported growth from a year ago at the $309 million midpoint, inside the $302.5 million to $316.5 million range that the prior full-year plan implied by our math. With Riverpoint owned for the full quarter, the plan leaves underlying sales growth slowing to 5.6% by our math.
Raised at the bottom of the range. Management lifted the middle of the target by $2.5 million to 16.0% reported growth and kept underlying sales growth at about 7%. It is the third raise this year—+$7.5M, +$87.5M on the acquisition, and +$2.5M. For 2027, Glastra also set an early target of more than 15% reported revenue growth.
New. At the $77.5 million middle of the range, EBITDA excluding one-offs grows 27.7% from a year ago, down from 38.3% growth in the third quarter. By our math, the outlook puts the fourth-quarter EBITDA margin at 25.1%, down 1.2 percentage points from the third quarter's 26.3%.
Unchanged at the $275.5 million midpoint. The technology supplier narrowed the range by $1 million on each side, keeping full-year growth at 24.7% from a year ago despite beating the third-quarter midpoint by $4.8 million.
Cut against what the prior full-year plan implied. The range calls for 0% to 5% growth from a year ago (2.7% at the $0.935 midpoint), down from 20.7% growth in the third quarter and below the $0.98 to $1.09 range implied three months ago by our math, as acquisition interest and share count weigh on profit.
Cut by 2.5 cents at the middle of the range. Even after beating the third-quarter plan by 7.5 cents at the midpoint, the company lowered the full-year range to 11% to 13% growth (12.0% at the $3.685 midpoint). The prior moves this year were $0.00, +$0.135 on the deal, and now -$0.025.
Raised from the $145 million to $185 million range issued at the start of the year. With $155.9 million collected in the first nine months, the target leaves about $44.1 million of operating cash flow for the fourth quarter by our math, compared with $8.8 million in the fourth quarter of last year.
❓ Key Questions
What are Riverpoint Medical's standalone sales and profit margins?
Novanta paid $1.20 billion upfront and owes a $250 million milestone, but the release combines all acquisitions into one $32.9 million revenue line. Investors need Riverpoint's standalone revenue and EBITDA to judge the price paid and the old medical unit's underlying growth.
Why did full-year profit per share fall after a third-quarter beat?
Third-quarter profit per share excluding one-offs beat the midpoint of the plan by 7.5 cents, yet management cut the full-year midpoint by 2.5 cents. How much of the fourth-quarter drop comes from higher debt interest versus operational dilution?
Did Novanta finish the delayed factory closures in the third quarter?
Management previously promised two site closures in the second quarter to remove duplicate factory costs, which went unconfirmed. With $3.9 million of new restructuring charges in the third quarter, how many of the five planned closures are now complete?
How will Novanta fund the $250 million January milestone payment?
Cash ended the quarter at $149.2 million and implied fourth-quarter operating cash flow is about $44 million by our math. Will the company draw further on its credit facility in January, and what will that add to 2027 interest expense?